Plain-English translation of NCT07905677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called in women with advanced ovarian cancer. is given as an injection directly into the abdomen once a week for four weeks. The trial is designed to find the right dose, understand how safe the medication is, and see if it can help slow or shrink the cancer.
Women with advanced ovarian cancer often run out of effective treatment options as their cancer develops resistance to standard therapies. This trial aims to offer a new option and determine whether this medication could benefit patients who have exhausted or cannot tolerate existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive as an injection into your abdomen once a week for four weeks (on days 1, 8, 15, and 22). The study starts with lower doses and increases them gradually to find the safest dose. You will have regular appointments to check for side effects, have blood tests and physical exams, and undergo imaging scans to see how your cancer is responding to the treatment. The trial involves about 22 women total, and the entire process is designed to gather safety information and early signs of how well the medication works.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States